ERAS Erasca | $13.66 -1.7% | 11/17/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Erasca (NASDAQ:ERAS) on 11/17/2026 |
VTRS Viatris | $20.33 -0.6% | 11/17/2026 | | Boost Price Target | $22.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 11/17/2026 |
BNTC Benitec Biopharma | $8.24 +1.1% | 11/16/2026 | | Boost Price Target | $18.00 ➝ $18.27 | Outperform | 00.00% | View details for Leerink Partners rating of Benitec Biopharma (NASDAQ:BNTC) on 11/16/2026 |
PVLA Palvella Therapeutics | $145.80 +1.0% | 11/16/2026 | | Initiated Coverage | $228.00 | Outperform | 00.00% | View details for Leerink Partners rating of Palvella Therapeutics (NASDAQ:PVLA) on 11/16/2026 |
BLTE Belite Bio | $156.94 -0.5% | 11/13/2026 | | Boost Price Target | $185.00 ➝ $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Belite Bio (NASDAQ:BLTE) on 11/13/2026 |
ENGN enGene | $1.81 +4.9% | 11/13/2026 | | Upgrade | $5.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 11/13/2026 |
KARD Kardigan | $12.68 -3.9% | 11/13/2026 | | Lower Price Target | $37.00 ➝ $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 11/13/2026 |
NPCE NeuroPace | $8.19 -0.1% | 11/13/2026 | | Downgrade | $7.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of NeuroPace (NASDAQ:NPCE) on 11/13/2026 |
TWST Twist Bioscience | $115.77 +3.4% | 11/13/2026 | | Lower Price Target | $190.00 ➝ $175.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 11/13/2026 |
MANE Veradermics | $124.37 -1.0% | 11/9/2026 | | Boost Price Target | $135.00 ➝ $150.00 | Outperform | 00.00% | View details for Leerink Partners rating of Veradermics (NYSE:MANE) on 11/9/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
HALO Halozyme Therapeutics | $95.73 -0.3% | 11/6/2026 | | Downgrade | $110.00 ➝ $117.00 | Outperform ➝ Hold | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 11/6/2026 |
AHCO AdaptHealth | $7.29 -3.3% | 11/5/2026 | | Boost Price Target | $7.00 ➝ $8.00 | Outperform | 00.00% | View details for Leerink Partners rating of AdaptHealth (NASDAQ:AHCO) on 11/5/2026 |
AMGN Amgen | $444.13 -3.0% | 11/5/2026 | | Boost Price Target | $395.00 ➝ $464.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Amgen (NASDAQ:AMGN) on 11/5/2026 |
AMRX Amneal Pharmaceuticals | $21.79 +3.2% | 11/5/2026 | | Boost Price Target | $23.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 11/5/2026 |
BRKR Bruker | $63.12 +2.9% | 11/5/2026 | | Boost Price Target | $80.00 ➝ $85.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 11/5/2026 |
COR Cencora | $347.61 -0.8% | 11/5/2026 | | Boost Price Target | $388.00 ➝ $405.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 11/5/2026 |
CVS CVS Health | $81.34 -5.2% | 11/5/2026 | | Lower Price Target | $112.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 11/5/2026 |
CYTK Cytokinetics | $51.53 -0.2% | 11/5/2026 | | Lower Price Target | $103.00 ➝ $100.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cytokinetics (NASDAQ:CYTK) on 11/5/2026 |
EW Edwards Lifesciences | $105.34 -0.1% | 11/5/2026 | | Boost Price Target | $101.00 ➝ $112.00 | Outperform | 00.00% | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 11/5/2026 |
EXEL Exelixis | $68.46 -0.1% | 11/5/2026 | | Boost Price Target | $55.00 ➝ $58.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 11/5/2026 |
INCY Incyte | $118.24 -0.7% | 11/5/2026 | | Lower Price Target | $154.00 ➝ $150.00 | Outperform | 00.00% | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 11/5/2026 |
MCK McKesson | $1,081.70 -0.9% | 11/5/2026 | | Boost Price Target | $1,070.00 ➝ $1,200.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 11/5/2026 |
MDLN Medline | $39.04 +3.6% | 11/5/2026 | | Boost Price Target | $43.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medline (NASDAQ:MDLN) on 11/5/2026 |
MIRM Mirum Pharmaceuticals | $92.26 +0.3% | 11/5/2026 | | Lower Price Target | $154.00 ➝ $140.00 | Outperform | 00.00% | View details for Leerink Partners rating of Mirum Pharmaceuticals (NASDAQ:MIRM) on 11/5/2026 |
MYGN Myriad Genetics | $5.62 +1.4% | 11/5/2026 | | Boost Price Target | $5.00 ➝ $8.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Myriad Genetics (NASDAQ:MYGN) on 11/5/2026 |
PGNY Progyny | $36.05 -1.8% | 11/5/2026 | | Boost Price Target | $37.00 ➝ $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 11/5/2026 |
PODD Insulet | $140.09 -3.6% | 11/5/2026 | | Boost Price Target | $143.00 ➝ $167.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 11/5/2026 |
PRCT PROCEPT BioRobotics | $25.17 +5.9% | 11/5/2026 | | Boost Price Target | $20.00 ➝ $22.00 | Market Perform | 00.00% | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 11/5/2026 |
RCUS Arcus Biosciences | $15.91 -2.9% | 11/5/2026 | | Boost Price Target | $46.00 ➝ $49.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcus Biosciences (NYSE:RCUS) on 11/5/2026 |
TEVA Teva Pharmaceutical Industries | $42.15 -1.1% | 11/5/2026 | | Boost Price Target | $45.00 ➝ $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 11/5/2026 |
TVTX Travere Therapeutics | $50.10 -2.0% | 11/5/2026 | | Lower Price Target | $78.00 ➝ $67.00 | Outperform | 00.00% | View details for Leerink Partners rating of Travere Therapeutics (NASDAQ:TVTX) on 11/5/2026 |
VCYT Veracyte | $25.37 +4.7% | 11/5/2026 | | Downgrade | $55.00 ➝ $35.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Veracyte (NASDAQ:VCYT) on 11/5/2026 |
VRDN Viridian Therapeutics | $30.17 +0.3% | 11/5/2026 | | Boost Price Target | $50.00 ➝ $54.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viridian Therapeutics (NASDAQ:VRDN) on 11/5/2026 |
RTSN Retension Pharmaceuticals | $13.69 +20.0% | 11/3/2026 | | Initiated Coverage | | Strong-Buy | 00.00% | View details for Leerink Partners rating of Retension Pharmaceuticals (NASDAQ:RTSN) on 11/3/2026 |
ABBV AbbVie | $286.36 -2.2% | 11/2/2026 | | Boost Price Target | $309.00 ➝ $342.00 | Outperform | 00.00% | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 11/2/2026 |
BTSG BrightSpring Health Services | $68.53 -1.9% | 11/2/2026 | | Boost Price Target | $72.00 ➝ $92.00 | Outperform | 00.00% | View details for Leerink Partners rating of BrightSpring Health Services (NASDAQ:BTSG) on 11/2/2026 |
REGN Regeneron Pharmaceuticals | $945.29 -1.3% | 11/2/2026 | | Boost Price Target | $835.00 ➝ $997.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 11/2/2026 |
THC Tenet Healthcare | $269.62 -4.4% | 11/2/2026 | | Boost Price Target | $309.00 ➝ $342.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 11/2/2026 |
AXGN AxoGen | $56.87 +2.7% | 10/29/2026 | | Boost Price Target | $52.00 ➝ $56.00 | Outperform | 00.00% | View details for Leerink Partners rating of AxoGen (NASDAQ:AXGN) on 10/29/2026 |
BSX Boston Scientific | $43.68 +1.5% | 10/29/2026 | | Lower Price Target | $55.00 ➝ $50.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/29/2026 |
A Bill Would Reprice America's Gold at Market Value (Ad) The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books.
A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years. Request your free 2026 Gold Guide to see what repricing could mean for you. |
REPL Replimune Group | $19.71 +0.1% | 10/29/2026 | | Boost Price Target | $19.00 ➝ $31.00 | Outperform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 10/29/2026 |
LH Labcorp | $370.18 +0.5% | 10/28/2026 | | Set Price Target | $410.00 | | 00.00% | View details for Leerink Partners rating of Labcorp (NYSE:LH) on 10/28/2026 |
WVE WAVE Life Sciences | $2.79 -1.9% | 10/27/2026 | | Set Price Target | $10.00 | | 00.00% | View details for Leerink Partners rating of WAVE Life Sciences (NASDAQ:WVE) on 10/27/2026 |
DXCM DexCom | $82.49 +0.5% | 10/26/2026 | | Lower Price Target | $94.00 ➝ $87.00 | Outperform | 00.00% | View details for Leerink Partners rating of DexCom (NASDAQ:DXCM) on 10/26/2026 |
ISRG Intuitive Surgical | $422.52 -1.9% | 10/21/2026 | | Set Price Target | $473.00 ➝ $503.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 10/21/2026 |
LLY Eli Lilly and Company | $1,386.32 -2.1% | 10/21/2026 | | Boost Price Target | $1,309.00 ➝ $1,316.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 10/21/2026 |
KZIA Novogen | $5.46 +2.7% | 10/20/2026 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Leerink Partners rating of Novogen (NASDAQ:KZIA) on 10/20/2026 |
UTHR United Therapeutics | $579.37 -0.8% | 10/19/2026 | | Boost Price Target | $685.00 ➝ $725.00 | Outperform | 00.00% | View details for Leerink Partners rating of United Therapeutics (NASDAQ:UTHR) on 10/19/2026 |
TRAX First Tracks Biotherapeutics | $44.50 +2.1% | 10/16/2026 | | Boost Price Target | $70.00 ➝ $90.00 | Outperform | 00.00% | View details for Leerink Partners rating of First Tracks Biotherapeutics (NASDAQ:TRAX) on 10/16/2026 |
JNJ Johnson & Johnson | $273.66 -1.8% | 10/14/2026 | | Lower Price Target | $276.00 ➝ $272.00 | Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 10/14/2026 |
XRAY DENTSPLY SIRONA | $8.52 -1.0% | 10/14/2026 | | Lower Price Target | $14.00 ➝ $10.00 | Market Perform | 00.00% | View details for Leerink Partners rating of DENTSPLY SIRONA (NASDAQ:XRAY) on 10/14/2026 |
NVST Envista | $23.76 +0.3% | 10/14/2026 | | Lower Price Target | $35.00 ➝ $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Envista (NYSE:NVST) on 10/14/2026 |
HSIC Henry Schein | $85.60 +3.2% | 10/14/2026 | | Set Price Target | $96.00 ➝ $92.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Henry Schein (NASDAQ:HSIC) on 10/14/2026 |
ALGN Align Technology | $163.72 +0.2% | 10/14/2026 | | Lower Price Target | $235.00 ➝ $215.00 | Outperform | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 10/14/2026 |
CNTB Connect Biopharma | $0.62 +6.4% | 10/12/2026 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Connect Biopharma (NASDAQ:CNTB) on 10/12/2026 |
CVS CVS Health | $81.34 -5.2% | 10/12/2026 | | Lower Price Target | $119.00 ➝ $112.00 | Outperform | 00.00% | View details for Leerink Partners rating of CVS Health (NYSE:CVS) on 10/12/2026 |
EQ Equillium | $1.08 -11.2% | 10/12/2026 | | Initiated Coverage | $6.00 | Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 10/12/2026 |
NKTR Nektar Therapeutics | $34.75 -3.2% | 10/12/2026 | | Initiated Coverage | $130.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nektar Therapeutics (NASDAQ:NKTR) on 10/12/2026 |
PTGX Protagonist Therapeutics | $126.80 +1.7% | 10/12/2026 | | Initiated Coverage | $150.00 ➝ $190.00 | Outperform | 00.00% | View details for Leerink Partners rating of Protagonist Therapeutics (NASDAQ:PTGX) on 10/12/2026 |
QTTB Q32 Bio | $8.58 -0.5% | 10/12/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Q32 Bio (NASDAQ:QTTB) on 10/12/2026 |
VERA Vera Therapeutics | $25.66 -2.1% | 10/12/2026 | | Initiated Coverage | $34.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Vera Therapeutics (NASDAQ:VERA) on 10/12/2026 |
ARCT Arcturus Therapeutics | $7.91 -0.8% | 10/9/2026 | | Boost Price Target | $13.00 ➝ $19.00 | Outperform | 00.00% | View details for Leerink Partners rating of Arcturus Therapeutics (NASDAQ:ARCT) on 10/9/2026 |
BSX Boston Scientific | $43.68 +1.5% | 10/9/2026 | | Lower Price Target | $60.00 ➝ $55.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 10/9/2026 |
SYK Stryker | $317.76 +0.1% | 10/9/2026 | | Lower Price Target | $403.00 ➝ $353.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 10/9/2026 |
IQV IQVIA | $258.30 +0.3% | 10/8/2026 | | Boost Price Target | $280.00 ➝ $310.00 | Outperform | 00.00% | View details for Leerink Partners rating of IQVIA (NYSE:IQV) on 10/8/2026 |
CRBU Caribou Biosciences | $0.33 -3.1% | 10/7/2026 | | Downgrade | $4.00 ➝ $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026 |
COR Cencora | $347.61 -0.8% | 10/7/2026 | | Boost Price Target | $380.00 ➝ $388.00 | Outperform | 00.00% | View details for Leerink Partners rating of Cencora (NYSE:COR) on 10/7/2026 |
CRBU Caribou Biosciences | $0.33 -3.1% | 10/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Caribou Biosciences (NASDAQ:CRBU) on 10/7/2026 |
MCK McKesson | $1,081.70 -0.9% | 10/7/2026 | | Boost Price Target | $1,030.00 ➝ $1,070.00 | Outperform | 00.00% | View details for Leerink Partners rating of McKesson (NYSE:MCK) on 10/7/2026 |
OABI OmniAb | $5.07 +0.3% | 10/7/2026 | | Boost Price Target | $10.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of OmniAb (NASDAQ:OABI) on 10/7/2026 |
RCKT Rocket Pharmaceuticals | $2.13 +0.7% | 10/7/2026 | | Lower Price Target | $7.00 ➝ $4.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 10/7/2026 |
BMY Bristol Myers Squibb | $59.72 -2.7% | 10/5/2026 | | Downgrade | $73.00 ➝ $59.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Bristol Myers Squibb (NYSE:BMY) on 10/5/2026 |
ORIC Oric Pharmaceuticals | $7.65 -4.4% | 10/5/2026 | | Initiated Coverage | $26.00 | Outperform | 00.00% | View details for Leerink Partners rating of Oric Pharmaceuticals (NASDAQ:ORIC) on 10/5/2026 |
ZNTL Zentalis Pharmaceuticals | $1.39 -6.5% | 10/5/2026 | | Initiated Coverage | $4.00 ➝ $8.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Zentalis Pharmaceuticals (NASDAQ:ZNTL) on 10/5/2026 |
TXG 10x Genomics | $56.51 +0.4% | 9/29/2026 | | Boost Price Target | $40.00 ➝ $90.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/29/2026 |
TWST Twist Bioscience | $115.77 +3.4% | 9/29/2026 | | Boost Price Target | $160.00 ➝ $190.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/29/2026 |
ILMN Illumina | $209.36 +3.3% | 9/29/2026 | | Boost Price Target | $220.00 ➝ $300.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 9/29/2026 |
BRKR Bruker | $63.12 +2.9% | 9/29/2026 | | Boost Price Target | $60.00 ➝ $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 9/29/2026 |
ACHC Acadia Healthcare | $37.51 -1.1% | 9/23/2026 | | Boost Price Target | $30.00 ➝ $33.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Acadia Healthcare (NASDAQ:ACHC) on 9/23/2026 |
ANAB AnaptysBio | $46.46 +1.9% | 9/23/2026 | | Lower Price Target | $90.00 ➝ $81.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 9/23/2026 |
CLDX Celldex Therapeutics | $27.61 -1.5% | 9/23/2026 | | Boost Price Target | $70.00 ➝ $88.00 | Outperform | 00.00% | View details for Leerink Partners rating of Celldex Therapeutics (NASDAQ:CLDX) on 9/23/2026 |
LXEO Lexeo Therapeutics | $3.01 +5.3% | 9/23/2026 | | Reiterated Rating | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 9/23/2026 |
OBX Obsidian Therapeutics | $12.42 +2.9% | 9/22/2026 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Obsidian Therapeutics (NASDAQ:OBX) on 9/22/2026 |
BLSM BlossomHill Therapeutics | $14.66 -3.1% | 9/21/2026 | | Boost Price Target | $36.00 ➝ $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/21/2026 |
VRTX Vertex Pharmaceuticals | $538.57 +0.8% | 9/21/2026 | | Initiated Coverage | $594.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/21/2026 |
ELOX Eloxx Pharmaceuticals | $11.15 -5.0% | 9/18/2026 | | Set Price Target | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ARDT Ardent Health | $14.37 -19.0% | 9/18/2026 | | Reiterated Rating | $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 9/18/2026 |
ELOX Eloxx Pharmaceuticals | $11.15 -5.0% | 9/18/2026 | | Upgrade | $32.00 | Strong-Buy | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ENTX Entera Bio | $3.19 +6.2% | 9/18/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Entera Bio (NASDAQ:ENTX) on 9/18/2026 |
HCA HCA Healthcare | $473.58 -5.5% | 9/18/2026 | | Reiterated Rating | $492.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 9/18/2026 |
You missed yesterday's deadline… (Ad) In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years.
While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. See which company controls this entire energy discovery now. |
THC Tenet Healthcare | $269.62 -4.4% | 9/18/2026 | | Reiterated Rating | $309.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 9/18/2026 |
UHS Universal Health Services | $186.10 -3.1% | 9/18/2026 | | Boost Price Target | $198.00 ➝ $205.00 | Outperform | 00.00% | View details for Leerink Partners rating of Universal Health Services (NYSE:UHS) on 9/18/2026 |
TWST Twist Bioscience | $115.77 +3.4% | 9/17/2026 | | Boost Price Target | $120.00 ➝ $160.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/17/2026 |
BBNX Beta Bionics | $14.35 -2.5% | 9/14/2026 | | Boost Price Target | $24.00 ➝ $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 9/14/2026 |
LRMR Larimar Therapeutics | $3.23 +7.9% | 9/14/2026 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 9/14/2026 |
PTCT PTC Therapeutics | $60.06 -0.5% | 9/14/2026 | | Initiated Coverage | $98.00 | Hold ➝ Outperform | 00.00% | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/14/2026 |
RYTM Rhythm Pharmaceuticals | $119.12 +2.1% | 9/14/2026 | | Initiated Coverage | $133.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 9/14/2026 |
XERS Xeris Biopharma | $16.95 +0.9% | 9/10/2026 | | Boost Price Target | $12.00 ➝ $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 9/10/2026 |
BBOT BridgeBio Oncology Therapeutics | $1.82 -6.4% | 9/10/2026 | | Lower Price Target | $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026 |
PHVS Pharvaris | $31.43 -2.6% | 9/9/2026 | | Boost Price Target | $50.00 ➝ $65.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |